Neovasc Inc. NVCN
30.03 0.00 (+0.00%)
At closeApr 10, 2023, 4:00 PM EDT
29.43 Day range 30.07
52-week range unavailable
- Market cap
- 82.86M
- Shares out
- 2.76M
- Forward P/E
- -2.91
- Volume
- 1
- Open
- 29.59
- Previous close
- 30.03
- Day's range
- 29.43 – 30.07
- Analysts
- Hold
- Price target
- 24.00 (-20.1%)
- Earnings date
- May 11, 2023
3M +2.39 (+8.65%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 1.05%
- 50-day average
- 29.31
- 200-day average
- 15.47
Analyst view
Consensus: hold
Hold
Price target (mean) 24.00 -20.1% downside
Now 30.03
- Target (low)
- 20.00
- Target (mean)
- 24.00
- Target (high)
- 28.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
May 11, 2023
Expected May 11, 2023. Consensus EPS estimate -2.71.
Financials — quick view
NVCN Revenue — quarterly 1.45M
NVCN Net income — quarterly -13.84M
NVCN EPS — quarterly -5.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 11, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 31, 2023 | Dec 1, 2022 | -1.93 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -2.82 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.25 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -1.25 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -2.50 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2020 | SVB Leerink | main | — | Outperform |
| Nov 25, 2020 | H.C. Wainwright | reit | — | Buy |
| Nov 25, 2020 | Canaccord Genuity | main | — | Buy |
| Nov 25, 2020 | H.C. Wainwright | init | — | Buy |
| Nov 25, 2020 | Leerink Swann | main | Outperform | Outperform |
| Nov 25, 2020 | Canaccord Genuity | main | Buy | Buy |
About Neovasc Inc.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. As of April 11, 2023, Neovasc Inc. operates as a subsidiary of Shockwave Medical, Inc.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Canada
- Website
- neovasc.com
News
Shockwave Medical, Inc. Completes Acquisition of Neovasc 
Shockwave Medical Completes Acquisition of Neovasc 
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update 
Neovasc Shareholders Approve Acquisition by Shockwave Medical 
A Bull Market Is Coming: 1 Outstanding Growth Stock Down 36% to Buy and Hold 
Neovasc Announces German Reimbursement Renewal 
Mergers and Acquisitions in 2023 Off To A Strong Start 
Shockwave Medical To Buy Neovasc: Details (NVCN) 
Shockwave Medical to Acquire Neovasc 
Neovasc (NVCN) is on the Move, Here's Why the Trend Could be Sustainable
Your note
Sign in to keep a note on NVCN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Becker (Lisa Ann McFadde) | Senior Officer of Issuer | Exercise of rights | Aug 17, 2022 | 2,451 |
| Clark, Christopher John | Senior Officer of Issuer | Exercise of rights | Jun 21, 2022 | 49,095 |
| Colen (Fredericus A) | Senior Officer of Issuer | Exercise of rights | Jun 21, 2022 | 224,154 |
| Gallagher (Sarah Marie Hodgson) | Senior Officer of Issuer | Exercise of rights | Aug 17, 2022 | 1,458 |
| Geyer (Paul) | 10% Security Holder of Issuer | Acquisition or disposition in the public market | Nov 17, 2022 | 18,335 |
| Janzen (Doug) | Director of Issuer | Acquisition or disposition in the public market | Aug 18, 2022 | 38,779 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Natixis | 1.84% | 49,778 | 1.49M | Dec 30, 2022 |
| U.S. Capital Wealth Advisors, LLC | 0.69% | 18,780 | 563.96K | Dec 30, 2022 |
| Magnetar Financial LLC | 0.58% | 15,804 | 474.59K | Dec 30, 2022 |
| Choreo, LLC | 0.46% | 12,440 | 373.57K | Dec 30, 2022 |
| Morgan Stanley | 0.13% | 3,635 | 109.16K | Dec 30, 2022 |
| Bank of America Corporation | 0.10% | 2,701 | 81.11K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 854 | 25.64K | Nov 29, 2022 |